SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001640334-23-000844
Filing Date
2023-05-12
Accepted
2023-05-12 16:52:13
Documents
48
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 6-K nymox_6k.htm   iXBRL 6-K 36657
2 QUARTERLY REPORT nymox_ex991.htm   iXBRL EX-99.1 363099
3 CERTIFICATIONS nymox_ex992.htm EX-99.2 15014
4 CERTIFICATIONS nymox_ex993.htm EX-99.3 12694
10 nymox_ex991img1.jpg GRAPHIC 5630
  Complete submission text file 0001640334-23-000844.txt   1951678

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA nymox-20230331.xsd EX-101.SCH 38702
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE nymox-20230331_lab.xml EX-101.LAB 136623
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE nymox-20230331_cal.xml EX-101.CAL 32133
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nymox-20230331_pre.xml EX-101.PRE 110658
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nymox-20230331_def.xml EX-101.DEF 50539
42 EXTRACTED XBRL INSTANCE DOCUMENT nymox_6k_htm.xml XML 265744
Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2
Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2 1-800-936-9669
NYMOX PHARMACEUTICAL CORP (Filer) CIK: 0001018735 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-12033 | Film No.: 23916703
SIC: 2835 In Vitro & In Vivo Diagnostic Substances